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and M. M. STEVENSON, M.B., B.Ch.
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AMONG the bleeding disorders, hxmophilia has always attracted the greatest
interest. The familial nature of the disease, its early onset in life, its predilection
for males, and the inefficiency of the blood clotting have all been recognized.
Recent work, however, has cast doubt on the long-established view that
homophilia is a single entity. It has been shown that all cases, which present
clinically as hamophilia and which have a characteristic hereditary pattern, do
not necessarily have the same basic defect in the blood. Indeed the impaired
blood coagulation may be due to the deficiency of one of three clotting factors.
As it is impossible to differentiate these types of himophilia on clinical grounds
the final diagnosis can only be made in the laboratory.
In 1955, in co-operation with the Medical Research Council, we carried out a
survey of all possible hxmophilics in Northern Ireland. We began with a nucleus
of patients already known to us. With the help of the Northern Ireland Hospitals
Authority and Northern Ireland General Health Services Board, we were able
to approach the great majority of family doctors and consultants in Northern
Ireland, from whom we received every co-operation. Although no survey of this
kind can claim to be complete, we believe it to represent the majority of the
"bleeders" in Northern Ireland. We established a register of all hemophilics in
this area and offered facilities for the treatment of bleeding episodes. In co-
operation with the Dental Department of the Royal Victoria Hospital, we
introduced a service for regular dental inspection and conservative treatment.
We feel that the information obtained during this survey and our subsequent
experience in management are of sufficient general interest to warrant publication.
WHAT IS HAEMOPHILIA?
The older workers recognized this disorder by the presence of a classical triad
which consisted of:
(a) A persistent bleeding tendency in a male appearing in early life.
(b) A positive family history or characteristic hereditary pattern.
(c) A delayed blood-clotting.
While not all cases show the combination of typical clinical manifestations,
characteristic hereditary pattern, or evidence of delayed blood-clotting, yet all
have a deficiency in a blood-clotting factor. Nowadays the more modem
laboratory tests have allowed the precise determination of the clotting factor
responsible for this bleeding disorder. This has led to the discovery that cases
of ha!mophilia with similar clinical and hereditary manifestations may have
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Edifferent clottinig factor deficienicies. The factor which is deficient in classical
haxmophilia is antihaemophilic factor. Biggs, et al. (1952), described some cases
of a haemophilic-like condition which was due, not to a deficiency in anti-
hxmophilic factor, but to another factor also necessary for thromboplastin
formation. This was called Christmas factor after the surname of the first patient
in whom the defect was recognized. This factor is probably identical with plasma
thromboplastin component deficiency described independently by Aggeler, et al.
(1952), in America. More recently Rosenthal, et al. (1953), have described a
haemophilic-like disease with deficiency of a factor, which they call plasma
thromboplastin antecedent. Thus at least three types of hoemophilia exist. These
are often referred to as classical haemophilia or haemophilia A, Christmas disease
or haemophilia B and plasma thromboplastin antecedent deficiency or haemophilia C.
We have discovered, just as in other surveys of this kind, that there are
clinically mild cases of classical hxmophilia who show a definite deficiency in
antihxmophilic factor. Such patients may only bleed when subjected to gross
trauma or operative procedures. The possibility of a bleeding disorder may not be
seriously considered oni clinical grounds and is only brought to light by laboratory
tests. Hence classical homophilia cannot be entirely restricted to the clinical
syndrome but must depend mainly for diagnosis on the laboratory findings. We
have, therefore, utilised the following criterix for the diagnosis of classical
hxmophilia: (a) a history of a bleeding tendency; (b) a qualitative deficiency
of antihxniophilic factor; (c) a quantitative level of less than 30 per cent. of
antihxmophilic factor. The hereditary pattern was also investigated and is
discussed later. As a characteristic pattern was found in less than half the cases
investigated it was only used as corroborative evidence.
LABORATORY TESTS USED IN DIAGNOSIS.
During the course of this investigation five tests have been utilised for the
diagnosis of hoemophilia.
1. Clotting Time.
The capillarv technique for the determination of the clotting time is capricious
and therefore generally regarded as unsatisfactory. The tube technique of Lee
and White (1913), which attempts to ensure that an equal area of water-wettable
glass surface is exposed to the blood, provides more reliable and reproducible
results. By this method normal blood should clot within ten minutes.
2. P-rothrombin Time.
This test is normal in hxmophilics since the added tissue thromboplastin is able
to convert prothrombin to thrombin in the presence of calcium and hence change
the fibrinogen to fibrin.
The prothrombin test will detect deficiencies in prothrombin, factor V and
factor VII, and thus separate these disorders from the hxmophilic states. It is,
therefore, a useful screening test.
123. Prothrormbin Consumption Test.
When normal blood coagulates, the prothrombin is utilised in the process and
consequently very little can be detected in the serum an hour after clotting is
complete. The results can be expressed either as the percentage prothrombin
consumed or as the prothrombin activity of the serum. This latter test is called
the serum prothrombin activity (S.P.A.). The presence of less than 20 per cent.
prothrombin in the serum an hour after clotting can be regarded as normal.
It has been shown that the serum may still contain considerable amounts of
prothrombin an hour after blood from a hemophilic has clotted. This test is,
therefore, a somewhat indirect way of determining the efficiency of thrombo-
plastin generation. It is not specific for hamophilic states as it may also be
defective in conditions associated with thrombocytopenia.
4. Thromboplastin Generation Test.
It was the introduction of this test by Biggs and Douglas (1953) which made
possible the accurate diagnosis of hamophilia and its clear separation from other
coagulation defects. The development of the thromboplastin generation test has
been largely responsible for a world-wide impetus to the study of hamophilia.
The principle of the test is to measure in vitro the rate at which thromboplastin
is generated by the blood of an individual. Any significant reduction in the
amount of any of the coagulation factors will reduce the rate of thromboplastin
generation. In our hands we have found the thromboplastin generation test a
satisfactory way of diagnosing hamophilia. Usually a diagnosis of hxmophilia
can be made without the use of blood from a known hamophilic patient.
However, in some mild cases we have had to use hoemophilic plasma in order
to determine whether the plasma of the patient will correct the defect of a
known hoemophilic patient.
5. I'he Antihbemophilic Factor Assayy.
The assay of the amount of antihxmophilic factor present in the plasma is of
considerable value both in the diagnosis and in the management of hxmophilia.
We have found the method of Pitney (1956) to be most satisfactory from the
technical point of view and to give reproducible results.
THE INCIDENCE OF HAE1MOPHILIA IN NORTHERN IRELAND.
It is generally agreed that the incidence of hxmophilia is probably greater than
most people believe. Since more extensive surveys have been carried out, the
actual incidence has been found to be much greater than the hitherto accepted
or known incidence in the area involved. In Northern Ireland the total number
of "h2emophilics" so far discovered has been forty-three in a total and fairly
stable population of 1.75 x 106. Of these, thirty-nine were cases of classical
haemophilia givinig an incidence of 1 in 45,000 for this disease. This is comparable
with the incidenice given by Biggs and Macfarlane (1954) of two or three
haemophilics per 100,000 inhabitants in England.
13In any consideration of the epidemiology of hxmophilia there should be some
reference to the incidence of the different genetic defects. Among our cases we
have found no examples of plasma thromboplastin antecedent deficiency or
htmophilia C. Like other workers, we found families formerly regarded as
classical hoemophilia, who were in fact suffering from a deficiency in Christmas
factor and who had a normal plasma content of antihtmophilic factor. In all,
we found four cases of Christmas disease or h2mophilia B. The relative incidence
of the two types is shown in Table 1, together with the findings from some other
reported surveys.
TABLE 1.
PROPORTION OF PATIENTS WITH HARMOPHILIA AND
.CHRISTMAS DISEASE FROM PUBLISHED DATA.
CLASSICAL CHRI STMAS
HmEMOPHILIA DISEASE
England (Biggs and Macfarlane, 1958) - 220 ... 29
Switzerland - - - - 20 ... 10
U.S.A. (Frick, 1954) - - - 45 ... 10
Northern Ireland - - - - 39 ... 4
As might be expected, the proportion of hamophilia A to hemophilia B in
Northern Ireland is the same as that recorded by Biggs and Macfarlane for Great
Britain as a whole. It is less than the proportion found in America and in
Switzerland.
'CLINICAL FEATURES.
The clinical features of hemophilia are well known and we have little to add
to this aspect of the disease. As the condition is a hereditary defect, which
results in a predisposition to bleed readily, it is not surprising that the onset
frequently occurs in early life. In the majority of cases in our series the symptoms
had been present since infancy, but in a few the presenting symptoms did not
occur until adult life.
The bleeding tendency was episodic, varied in.severity, and had an undue
frequency in the spring. It was not possible to elicit any precipitating factors,
which would account satisfactorily for the clinical relapses. Mary patients
showed a tendency to reproduce the same hxmorrhagic pattern; some bled mainly
into joints, others into muscles, and others from the renal tract. However, a
combination of hxmorrhagic manifestations also occurred.
Severity of the bleeding varied from case to case and was fairly well correlated
with the antihemophilic factor level in the plasma. Mild cases were usually
associated with an antihaemophilic factor level above 10 per cent. The bleeding
in mild cases only followed surgical intervention or gross trauma. Five of our
cases were of this type. The type of presentation in the remainder varied but the
infrequency of epistaxis was notable.
14CORRELATION BETWEEN CLINICAL SEVERITY AND LABORATORY TESTS.
The correlation between the degree of clinical severity and the laboratory tests
used in diagnosis do not always show a very satisfactory relationship. The tests
which we will consider are the whole blood clotting time, the serum prothrombin
activity, and the antilixmophilic factor level.
1. Clotting Time.
It is well known that this test is unsatisfactory as a diagnostic laboratory method
in view of the fact that many hxmophilics have a normal clotting time (Fig. 1).
F;g 1
In general, however, it has been found that patients with a prolonged clotting
time usually have severe clinical manifestations. It does not, however, follow that
those with short clotting times are always mildly affected. Biggs and Macfarlane
have shown that of patients with normal or slightly increased clotting times
approximately half had severe clinical manifestations. Our own findings would
support this. Thus a normal or short clotting time does not exclude hamophilia
nor does it guarantee a mild form of the disease.
2. Serwn Prothrombin ActisAty.
This test appears to be more sensitive than the whole blood clotting time as a
means of assessing deficient thromboplastin formation. However, the test may
give normal results in spite of a deficiency in antihaemophilic factor. The results
obtained show a fair correlation with the degree of clinical severity (Table 2.)
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SERUM PROTHROMBIN ACTIVITY COMPARED WITH SEVERITY OF CASE.
SEVERITY OF S.P.A. %
DISEASE 0-20 20-40 40-60 '60-80 80+
Severe - - - ... - ... 1 ... 1 ... 14
Moderate - - 2 ... 1 ... 3 ...
Mild - - 3 ... 3 ...
.
3. Antih1emophilic Facto-r Level.
It would seem logical that the degree of the deficiency of the specific clotting
factor in the blood would correlate with the severity of the clinical manifestations.
In general, this has been found to be the case.
Since the introduction of the quantitative assay method it has been shown that
mild cases usually have an antihaemophilic factor level above 10 per cent., and
severely affected cases a level below 5 per cent. The levels of antihaemophilic
factor in seventeen of our patients are shown in Table 3 correlated with the
clinical grades of severity of the disease.
TABLE 3.
ANTIH]EMOPHILIC FACTOR LEVEL COMPARED WITH SEVERITY OF CASE.
SEVERITY OF A.H.F. %
DISEASE 0-5 5-10 10-15 15+
Severe - - 7 ... 2 ... -
Moderate - - 1 ... 1 ... - ...
Mild - - - ... 2 ... 1 ... 3
HEREDITARY PATTERN.
Hamophilia is transmitted as a sex linked recessive gene and therefore the
defect is located on the X chromosome. The daughter of a haemophilic male
must receive the character from her father and act as a carrier. The sons of a
hoemophilic male cannot receive the abnormal gene and are thus unaffected. The
haxmophilic female carrier who marries a non-haemophilic male will bear approxi-
mately equal numbers of normal and haemophilic sons and normal and hamophilic-
carrier daughters. A hxmophilic female carrier who marries a hamophilic male
will bear both haemophilic sons and hxmophilic daughters. These theoretical
considerations have been borne out in practice. Among humans some cases of
female hamophilics have been described, where the above criterix have been
satisfied but they are extremely rare (Merskey, 1951; Israels, et al., 1951). In
hemophilic dogs the mating of female carriers to male haemophilic animals has
produced haemophilic female dogs (Brinkhous and Graham, 1950). Figure 2
shows the idealised pattern of haemophilic inheritance.
16In conjunctioni with the Department of Social Medicine we have investigated
all the families of patients suffering from hamophilia in Northern Ireland. It has
been found that the family histories do not always reveal a bleeder on the
maternal side. We have obtained a positive family history in 45 per cent. of our
cases and in the remainder the disease appears to be sporadic. The sporadic cases
may be due to non-recognition of the disease in the forebears or to spontaneous
gene mutation. These findings are in conformity with those of other observers
(Biggs and Macfarlane, 1958).
HYPOTHETICAL FAMILY TREE of HAEMOPHILIA
O Normal Male Affected Males
( Normal Female (i Conductor Fermae Affected Female
Fiq 2
There is as yet no reliable way of recognising the female carrier. In our series
six mothers of haemophilic children were tested and in two a defect in anti-
hoemophilic factor was demonstrated. Their alumina-absorbed plasma, when
tested in a normal system, produced normal thromboplastin generation but failed
to correct the abnormal generation of known haemophilic plasma. This is to say,
of six female haemophilic carriers two had a partial antihanmophilic factor defect.
Similar results have been obtained in haemophilic carriers by Pitney (1958).
GENERAL MANAGEMENT.
As these patients are subject to repeated episodes of severe haemorrhage they
need to be admitted to hospital on numerous occasions. Many of these admissions
are emergencies which require special management. There is, therefore, much to
be said for the establishment of special centres for these patients, as has been
17organised in association with the Medical Research Council. Since haemophilia
is a chronic, and in its severe form, a very disabling disease, every effort is needed
to sustain morale and develop a healthy psychological approach to this life-long
disorder.
It is not proposed to deal with all aspects of treatment but only with the
treatment of a bleeding episode. Our experience in the management of dental
extraction will be the subject of a separate communication.
TREATMENT OF A BLEEDING EPISODE IN CLASSICAL HJEMOPHILIA.
There have in the past been many claims put forward in support of non-plasma
preparations for treatment but none have been substantiated. The only effective
therapeutic preparations are fresh whole blood, fresh plasma or some specially
TABLE 4.
EFFECT OF FRESH PLASMA AND CONCENTRATED PLASMA
ON ANTIHH)EMOPHILIC FACTOR LEVEL.
PLASMA
rRANSFUSION PRE-TRANSFUSION POST-TRANSFUSION A.H.F. % RISE
MLS. A.H.F. % A.H.F. % PER 100 ML.
500 ... 1.0 ... 7.0 ... 1.2
500 ... 3.0 ... 6.0 ... 0.6
750 ... 13.0 ... 18.0 ... 0.66 Av. 0.84
1,000 ... 0.5 ... 10.0 ... 0.95
1,000 ... 4;O ... 12.0 ... 0.8
CONCENTRATED A.H.F. PRE- POST-
Actual Equiv. TRANSFUSION TFRANSFUSION A.H.F. % RISE
Vol. (ml.) Vol. (ml.) A.H.F. % A.H.F. % PER 100 ML.
600 ... 1,200 ... 3.0 ... 10.0 ... 0.58
300 ... 600 ... .8. .. 5.0 0.70 Av. 0.73
300 ... 600 ... 1.2 ... 6.8 ... 0.93
processed fresh plasma. It is preferable to use plasma of human origin because
of its relative freedom from antigenic properties. Although animal plasma is high
in antihamophilic factor content it is strongly antigenic and consequently its use
is restricted. Animal plasma has been successfully employed to tide a patient over
an acute episode. Our experience has been mainly confined to the use of fresh
human plasma either used immediately or stored at - 20° C. for not more than ten
days and then allowed to thaw at room temperature prior to transfusion. We
have also used the dried human plasma processed according to the technique of
Kekwick and Wolf (1957) and kindly made available to us by Dr. Maycock of
the Lister Institute. We have found it to be therapeutically equivalent to the
volume of fresh wet plasma from which it was prepared.
18The response to therapy with wet and concentrated plasma are shown in
Table 4. It vill be seen from this that the antihxmophilic factor rise per 100 nil.
was comparable in both cases. However, the concentrated preparation has the
advantage of being contained in a smaller volume.
In the past the control of hamorrhage was frequently ineffective due to in-
adequate dosage. The object of plasma therapy is to raise the antihaemophilic
factor content of the blood of the patient to a hxmostatic level and to maintain
this level until bleeding is controlled. To achieve the first objective it is necessary
to have some understanding of the antihamophilic factor content in fresh and
stored plasma, the hemostatic level of antihaemophilic factor required and the
dose of plasma needed to reach this level. To achieve the second objective some
information on the survival of transfused antihamophilic factor in the circulation
is needed.
It is well known that the antihxmophilic factor is labile and therefore its
concentration dimiinishes on storage. The factors which influence the rate of
destruction are not fully understood, but there is some evidence to suggest that
minor clot formation in the stored blood utilises antihamophilic factor and
therefore reduces the amount available for therapeutic use. To achieve the
maximum yield of antihoemophilic factor, care in the details of collection,
separation, and storage are important. The main points are:-
1. Avoid frothing during collection.
2. Use of siliconed or non-water wettable apparatus.
3. Use of citrated anticoagulanit solution.
4. Careful mixitng with anticoagulant during collection.
5. Separation of plasma immediately after collection of blood in a refrigerated
centrifuge at 1,500 r.p.m.
6. Transfer of plasma immediately to a second cooled container.
7. Storage at - 20° C.
There is great variation in the levels of antihrmophilic factor among normal
individuals. The antihamophilic factor concentrations in normal plasmas may
vary from about 50 to 170 per cent. of the mean (Langdell, et al., 1953). The
antihaemophilic factor level of a given person appears to be relatively constant.
Brinkhous (1956) reported the results found in the study of antihamophilic factor
remaining in stored whole blood at 40 C., frozen plasma at - 200 C. and
lyophilized plasma. From these results he concluded that after two weeks' storage
whole blood retained over 50 per cent. of its initial antihaemophilic factor, whereas
after three weeks only very small amounts of antihoemophilic factor remained.
The deterioration in fresh frozen plasma was similar over the first two weeks but
the content then remained fairly stable. In a sample tested after eighteen weeks,
half of its initial activity remained. Brinkhous considers that the antihamophilic
factor content of fresh frozen plasma is approximately that of the lower limits
of the normal range in an adult.
To control bleeding, Biggs considers that an antihxmophilic factor level of
30 per cent. is required. This is not always easv to achieve. Langdell, Wagner,
19and Brinkhous (1955) suggested that an antihomophilic factor concentration
consistently maintained above 5 per cent. will control haemorrhage in many
instances and this has been our experience (Fig. 3). In an individual with a normal
blood volume, 1,500 ml. of plasma would be required to achieve a 30 per cent.
level of antihomophilic factor or 500 ml. to raise the antihaemophilic factor to
10 per cent. In practice we give a 1,000 ml. priming dose. It is important to
A.H1E Levels During Treatment with Plasma Transfusions
of a B'eeding Episode in a Haemophilic
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reach the hxmostatic level quickly, so this is given in 15-30 minutes under careful
supervision. We have not produced any circulatory overload with this procedure.
The maintenance of a hxmostatic level depends on the loss of antihamophilic
factor due to tissue hamorrhage and to decay arising from the short survival time
in the circulation of the transfused antihxmophilic factor. Aggeler (1956) has
shown that the half-life of antihemophilic factor in the hoemophilic is probably
less than twelve hours. However, Brinkhous, et al. (1956), consider that the
half-life is about four hours. In the one patient in whom this was studied we
found an approximate half-life of twelve hours. Because of the difficulty in
determining the maintenance dose of plasma required, we have been content to
use intermittent plasma therapy for our patients. We have found that the clinical
hemostatic effect of a plasma transfusion lasts twenty-four hours. Consequently
we have transfused these patients at 24 or sometimes at 48-hour intervals until
bleeding is controlled.
20Apart from systemic therapy, all ordinary surgical precautions must be observed.
In the care of wounds strict local hxmostasis by careful ligature of all bleeding
points and the use of suitable antibiotics to control secondary infection should
not be neglected. A useful measure in our experience in the treatment of
superficial wounds has been the use of topical thrombin incorporated in an
absorbable gelatin sponge.
PLASMA TRANSFUSION REACTIONS.
These may be due either to the presence of antibodies to antihaemophilic factor
or to some other plasma protein. In several of our patients this complication of
plasma transfusion has occurred. The reactions have been characterized by
urricarial wheals, erythema and bronchial spasm, thus closely resembling an acute
allergic reaction like serum sickness. In most cases we have found that the use
of antihistamines has proved effective in controlling these symptoms. However,
in severe or resistant cases we have had to give steroid hormones in addition.
CHRISTMAS DISEASE.
From the standpoint of hereditary transmission and haemorrhagic manifestations
this bleeding disorder resembles classical hxmophilia. Unlike classical haemophilia,
there is no deficiency of antiha!mophilic factor. Plasma from these patients
corrects the clotting defect of haemophilic patients both in vitro and in vivo.
This disease is due to the deficiency of a factor called Christmas factor, which is
activated during the coagulation of blood and can be demonstrated in serum
after clotting occurs.
The routine laboratory tests in Christmas disease are similar to those in classical
hoemophilia. The clotting time may be normal or prolonged. The prothrombin
time is normal. The prothrombin consumption may or may not be abnormal. The
thromboplastin generation test will demonstrate a normal concentration of anti-
haemophilic factor in the plasma and will detect a deficiency of Christmas factor
in the serum. The introduction of this test has allowed the clear separation of
classical haomophilia from Christmas disease.
In this survey only four cases of Christmas disease were seen as compared with
thirty-nine cases of classical hamophilia. In three of the four cases there was a
characteristic hereditary pattern of classical haemophilic type. From the clinical
point of view there is a belief that Christmas disease is a less severe form of
bleeding disorder. This is not so. Along with others we have found severe and
mild forms of both classical htmophilia and Christmas disease. Two of our four
cases of Christmas disease exhibited severe clinical manifestations of bleeding.
Furthermore, the brother of one of these latter patients was seen by one of us
before the present investigation started. He was known to be a bleeder, had been
diagnosed as haemophilia, and died following a gross haemorrhage into the psoas
nuscle. The laboratory findings and the clinical manifestations in our surviving
cases are presented in Table 5.
MANAGEMENT OF A BLEEDING EPISODE.
Cases of Christmas disease show a satisfactory clinical response to transfusions
of both blood and plasma. In this respect they behave like haemophilia. However,
21
HTABLE 5.
FINDINGS IN CHRISTAMAS DISEASE.
CLINICAL CLOrrING SERUM PROTHROMBIN
No. MANIFESTATIONS TIME AcTriviTY
1 ... Mild-easy bruising ... Normal- 6 mins. Normal
2 Mild-easy bruising and ...
hxmaturia ... Normal-10 mins. Normal
3 ... Severe-bruising, melxna,
hxmarthroses, retro-
peritoneal hxmorrhage ... 30 mins. + ... Abnormal
4 ... Severe-bruising and
haemarthroses ... 30 mins. + ... Abnormal
Christmas factor is more stable than antihxmophilic factor. As it is not used
during coagulation, it is found in blood serum. Furthermore, it is claimed that
Christmas factor, when transfused into a patient, has a long half-life and may
remain in the circulation for two to three weeks (Beaumont, et al., 1954). For
these reasons, the management of a bleeding episode is much simpler in Christmas
disease than in classical haemophilia. Although our clinical experience of the treat-
ment of Christmas disease has been limited, we have noted the ease with which
plasma transfusions have controlled bleeding episodes. As the Christmas factor is
stable, it is possible to use either plasma or serum for transfusion. It must be
remembered, however, that serum is of no value in the treatment of classical
haxmophilia and therefore accurate diagnosis is essential before such therapy is
used in 'hxmophilia.' We have used plasma from bank blood stored at 40 C. for
not more than twenty-one days and found it to be therapeutically effective in
Christmas disease. A single transfusion of as little as 1,000 mls. caused immediate
and permanent cessation of clinical bleeding, maintenance therapy not being
required. SUMMARY.
A survev has been made of hamophilia in Northern Ireland. Thirty-nine cases
of classical hxmophilia have been found in the population in this area, giving an
incidence of one in 45,000. A study of the hereditary pattern has revealed a
positive family history in 45 per cent. of our cases.
The value of laboratory tests in the diagnosis of ha!mophilia was studied. On
the tests used the clotting time was found to be least valuable, being normal in
one-third of the cases. The serum prothrombin activity was a more useful
diagnostic test but the most valuable was the thromboplastin generation test. A
modification of this test allows a quantitative estimation of the antihaemophilic
factor in the plasma to be made.
The clinical severity of the cases was found to correlate with the level of
antihaemophilic factor in the plasma. Mild cases had a level above 10 per cent. and
severe cases a level below 5 per cent.
22The management of bleeding episodes in classical hxmophilia is described.
The importance of rapid and adequate plasma transfusion to attain a haemostatic
level of antihoemophilic factor is stressed.
Four cases of Christmas disease have also been studied and a positive family
history obtained in three of these. The hereditary pattern and clinical manifes-
tations were identical with classical haemophilia. Differential diagnosis can only
be established using the thromboplastin generation test. The management of
bleedinig episodes in Christmas disease is described. The relative ease in controlling
haemorrhage, even with small plasma transfusions, is pointed out. Christmas disease
can also be successfully treated by transfusion of serum. Because of this it is
important to establish an accurate diagnosis between these two conditions before
therapy is applied.
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